It has been a mixed year for Bicara Therapeutics Inc. insiders: $4.8 million bought by one person and $11.1 million sold by four, so more selling than buying overall.
RA CAPITAL MANAGEMENT, L.P. (Director) made the biggest buy, worth around $4.8 million.
2 quarters in a row of net selling by insiders. Insiders bought in 1 of the last 7 full quarters. 171 investment managers listed BCAX in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Cohlhepp Ryan | CEO | Sell | 3,442 | $23.43 | $81K | SEC |
| Sep 10, 2026 | Cohlhepp Ryan | CEO | Sell | 14,058 | $22.77 | $320K | SEC |
| Aug 12, 2026 | Hyep Ivan | CFO | Sell | 12,500 | $27.97 | $350K | SEC |
| Aug 12, 2026 | Mazumdar Claire | CEO | Sell | 10,000 | $27.98 | $280K | SEC |
| Aug 12, 2026 | Cohlhepp Ryan | COO | Sell | 18,750 | $27.98 | $525K | SEC |
| Jul 14, 2026 | Mazumdar Claire | CEO | Sell | 9,972 | $28.42 | $283K | SEC |
| Jul 14, 2026 | Mazumdar Claire | CEO | Sell | 28 | $29.68 | $831 | SEC |
| Jul 10, 2026 | Cohlhepp Ryan | COO | Sell | 22,833 | $28.76 | $657K | SEC |
| Jul 10, 2026 | Cohlhepp Ryan | COO | Sell | 536 | $29.00 | $16K | SEC |
| Jul 10, 2026 | Cohlhepp Ryan | COO | Sell | 1,075 | $30.35 | $33K | SEC |
| Jul 10, 2026 | Cohlhepp Ryan | COO | Sell | 4,306 | $29.80 | $128K | SEC |
| Jul 10, 2026 | Hyep Ivan | CFO | Sell | 830 | $30.31 | $25K | SEC |
| Jul 10, 2026 | Hyep Ivan | CFO | Sell | 22,757 | $28.60 | $651K | SEC |
| Jul 10, 2026 | Hyep Ivan | CFO | Sell | 4,413 | $29.82 | $132K | SEC |
| May 26, 2026 | Hyep Ivan | CFO | Sell | 9,200 | $20.42 | $188K | SEC |
In the last 12 months Bicara Therapeutics Inc. insiders made open-market purchases worth about $4.8 million and sales worth about $11.1 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in BCAX was filed on 2026-09-10.
171 investment managers reported holding BCAX in SEC Form 13F filings for Q2 2026.
No congressional trades in BCAX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).